Melanoma is among the most aggressive cancers due to its tendency to metastasize early. Phenotype switching between a proliferative and an invasive state has been suggested as a critical process for metastasis. The mechanisms that regulate these transitions are complex and remain poorly understood. Brother of Regulator of Imprinted Sites (BORIS), also known as CCCTC binding factor-Like (CTCFL), is a transcriptional modulator that becomes aberrantly expressed in melanoma. Here, we show that BORIS is involved in phenotype switching in melanoma. Genetic modification of BORIS expression in melanoma cells combined with whole transcriptome analysis indicated that BORIS expression contributes to an invasion-associated transcriptome. In agreement with this finding, inducible BORIS overexpression in melanoma cells reduced proliferation and increased migration and invasion, demonstrating that the transcriptional switch is accompanied by a phenotypic switch. Overall, our study indicates a pro-invasive role for BORIS in melanoma via transcriptional reprogramming.
Introduction
Primary cutaneous melanoma is one of the most aggressive cancers due to its ability to rapidly disseminate and develop distant metastases. The progression of melanoma from the primary site to regional lymph nodes and distant sites requires cells to migrate and invade into tissue containing lymphovascular channels that allow the tumor cells to enter the circulation. During melanoma progression, cells undergo phenotype switching by transitioning from a proliferative to an invasive state, a process similar to epithelial-mesenchymal transition (EMT) (1, 2) . Gene expression profiling of melanoma cell lines and tumor samples has revealed the different transcriptional states that underlie the proliferative and invasive phenotypes of melanoma cells (3) (4) (5) (6) (7) . While proliferative cells tend to express high levels of developmental and lineage specification genes such as MITF, MLANA, and DCT as well as SOX10 and PAX3 (1, 4, 6) , cells with an invasive transcriptional state are marked by expression of amongst others, ZEB1, SNAI1, AXL, NGFR, SPARC, WNT5A and genes involved in TGF-β signaling (4, (6) (7) (8) (9) (10) . Currently, various transcriptional regulators have been implicated as drivers of the transition towards an invasive phenotype, including BRN2, AP-1, TEAD, NFATC2, and NFIB (4, (11) (12) (13) (14) . These findings suggest complex transcriptional regulation that requires context-specific involvement of various signaling pathways, transcriptional regulators, and gene networks to achieve the transition towards an invasive state.
In line with this idea it was proposed that phenotype switching comprises a gradient of phenotypic states that is accompanied by different transcriptional states (15, 16) , similarly to what is reported for EMT in epithelial cancers (17, 18) . To gain insight into the transcriptional landscape that underlies these different phenotypic spectra it is important to identify transcriptional regulators of the gene expression changes that confer migratory and invasive properties to melanoma cells.
Brother of Regulator of Imprinted Sites (BORIS) is a DNA binding protein with high similarity to CCCTC binding factor (CTCF) (19) , a multifunctional transcription factor that plays an important role in genome organization (20) . In contrast to the tumor suppressive functions reported for CTCF (21, 22) , multiple studies have indicated an oncogenic role for BORIS (23) (24) (25) (26) (27) . Like CTCF, BORIS plays a role in transcriptional regulation (24, 25, 28, 29) . The mechanisms through which BORIS can alter transcription rely on BORIS' ability to bind the DNA at specific binding motifs, which are often found near promoter regions (30) (31) (32) . At these binding motifs BORIS can compete with DNA-bound CTCF (32) , form a BORIS-CTCF heterodimer, or occupy a so-called BORIS-only binding site (31) . Via these mechanisms BORIS can alter transcription by acting as a transcriptional activator (24, 25, 29, 33) , recruiting a transcriptional activator (34) , altering DNA methylation (24, 35, 36) or histone modifications (24, 28, 29, 35) , or recruiting chromatin modifying proteins (37, 38) . In addition, it is believed that BORIS impacts the transcriptional landscape by interfering with CTCF-mediated chromatin loops (31, 39) . The BORIS gene is located at 20q13 locus, within a chromosomal region that is often amplified in cancer (40) .
Furthermore, hypomethylation of the BORIS promoter is frequently observed in cancer cells (41, 42) . Besides regulation of expression via DNA methylation, increased BORIS levels have been observed upon CTCF knockdown (43) . BORIS is expressed in 60-90% of melanoma cell lines (36, 44) , in 16% (4 out of 25) of primary melanomas and in 34% (13 out of 38) of melanoma metastases (44) . The higher frequency of BORIS expression in metastatic tumors compared to primary tumors suggests that BORIS plays a role in melanoma progression (44) . Currently, little is known about the role of BORIS in melanoma.
In this study, we sought to determine if BORIS plays a role in melanoma progression through its role as transcriptional modulator. We found that BORIS expression in melanoma cells led to altered gene expression as determined by RNA-sequencing (RNA-seq). While the upregulated genes were enriched among invasion-related processes and gene signatures, the downregulated genes were enriched among proliferation-related processes and gene signatures, suggesting that BORIS plays a role in phenotype switching. Phenotypically, we found that BORIS overexpression reduced proliferation and increased the migratory and invasive ability of melanoma cell lines.
Overall, we demonstrate that BORIS-mediated transcriptional reprogramming was accompanied by a switch towards an invasive phenotype.
Results

BORIS expression in the MM057 melanoma cell line induces large-scale differential gene expression
First, we sought to confirm that BORIS is expressed in melanoma cell lines as reported previously (36, 43, 44) . Our panel of melanoma and non-malignant congenital nevi cell lines was screened for expression of BORIS mRNA and protein. This revealed BORIS mRNA in ~60% (11 out of 18, Fig S1A) and BORIS protein in ~33% (4 out of 12, Fig S1B) of melanoma cell lines. We did not detect BORIS expression in the congenital nevi cell lines (Fig S1A) . In the tested melanoma cell lines BORIS mRNA expression was not proportional to BORIS protein level. We observed no correlation between the expression of BORIS and its ubiquitously expressed paralogue CTCF in the tested cell lines ( Fig. S1B and C) . Together, these data indicate that BORIS is expressed in melanoma cells and that this expression is independent of CTCF expression.
Next, we wanted to assess if BORIS, through its role as transcriptional modulator, can alter the transcriptome of melanoma cells. To this end we used the MM057 melanoma cell line, which harbors a proliferative gene signature as reported by Verfaillie et al. (4) and expresses no detectable BORIS protein and low BORIS mRNA ( Fig. S1A and B) . The effect of BORIS expression on the transcriptome of MM057 cells was assessed by RNA-seq using three biological replicates. BORIS overexpression was established in this cell line by lentiviral transduction with the doxycycline (dox)-inducible BORIS expression vector and BORIS mRNA and protein levels were compared with those in the control cells for each independent RNA-seq sample ( Fig. 1A) . Since a strong correlation was observed between the biological replicates (r≥0.97, Fig. S2A ), all of the data was included for downstream analyses. The unsupervised analysis of gene expression demonstrated clustering of the samples into two groups, one representing the controls [empty vector without dox (EVneg) and with dox (EVpos), and BORIS without dox (BORneg] and the other representing BORIS expressing cells [BORIS with dox (BORpos)] (Fig S2B) . Differential gene expression analysis between BORneg and BORpos cells identified 2248 differential expressed genes (DEGs), of which 1361 genes were upregulated and 887 downregulated following BORIS expression ( Fig.   1B and Table S2 ). Analysis of the log2 counts per million (CPM) for the top 100 up-and downregulated genes demonstrated robust differential expression, as well as clustering of all control samples versus BORpos samples (Fig. 1C) . To validate the RNA-seq dataset, BORIS expression was induced in the MM057 cells and qPCR was performed for genes distributed throughout the list of DEGs. A significant differential expression of upregulated and downregulated genes was observed following BORIS expression compared to the controls (Fig. 1D) . Together, these data demonstrate that ectopic BORIS expression results in large-scale differential gene expression.
BORIS expression contributes to a switch from a proliferative to invasive transcriptional state
The dataset was further analyzed to investigate if BORIS-regulated genes are involved in processes related to melanoma progression. First, gene set enrichment analysis (GSEA) (45) was performed for biological processes on a pre-ranked gene list. A strong enrichment (false discovery rate (FDR)<0.05) for migration and invasion-related processes was observed, including EMT, cell motility and locomotion, while a strong negative enrichment was found for proliferation-related processes like cell cycle/division, telomere maintenance, and DNA replication/repair ( Fig. 2A) .
This analysis provides the first line of evidence that BORIS could promote a pro-invasive transcriptome in melanoma cells. Next, we performed GSEA for the melanoma-specific Hoek (3) and Verfaillie (4) gene signatures that correspond to either the proliferative or invasive state of melanoma cells. For these gene sets, we identified a strong positive correlation with the Hoek (NES=2.21, FDR=0.001) and Verfaillie (NES=5.99, FDR<10 -4 ) invasive gene signatures ( Fig. 2B) and a negative correlation with the Hoek (NES=-1.98, FDR=0.006) and Verfaillie (NES=-3.84, FDR<10 -4 ) proliferative gene signatures (Fig. 2C) . These data support the hypothesis that BORIS expression enables a transcriptional program that promotes a switch from a proliferative to invasive state. To validate the effect of BORIS expression on genes within the gene signatures we measured the expression of four invasion-associated and four proliferation-associated genes from the Hoek and Verfaillie studies in the MM057 cell line following BORIS expression. We observed a significant upregulation of the invasion-associated genes DKK1, FBN1, INHBA and VEGFC ( Fig. 2D ) and significant downregulation of the proliferation-associated genes GYG2, LZTS1, MLANA and TFAP2A ( Fig. 2E) compared to the controls. Together, these results indicate that BORIS promotes a switch from a proliferative to an invasive gene expression signature in melanoma cells.
Transcriptional reprogramming and subsequent phenotype switching have been linked to differences in the expression of transcription factors that are associated with EMT (4, 11, 12) . In melanoma, reduced expression of the melanoma-specific transcription factor MITF has been reported in invasive cells compared to proliferative cells (1) . MITF is regulated by the switch in expression from ZEB2 in melanocytes to ZEB1 in melanoma cells, with ZEB1 functioning as a transcriptional repressor of E-cadherin (CDH1) (46, 47) . In the MM057 cells BORIS did not significantly reduce MITF expression ( Fig. 3A) . Similarly, BORIS did not significantly alter ZEB1, ZEB2 (Fig. 3A) or CDH1 expression (not expressed). In contrast, expression of the transcription factor and melanoma EMT inducer SNAIL (SNAI1) (48) was increased in BORISexpressing MM057 cells (Fig. 3A) . Expression of SNAIL can be upregulated via multiple mechanisms, including elevated levels of the matricellular protein SPARC (49) and TGF-beta (48) .
Indeed, we observed significantly higher expression of SPARC and TGFB1 in BORIS-induced cells compared to non-induced cells (Fig. 3B) . Furthermore, the RNA-seq data reveals increased transcription of multiple genes belonging to the TGF-beta family (Fig. 3C) . These data suggest that the BORIS-induced transcriptional switch may be mediated via TGF-beta signaling and increased SNAI1 expression.
BORIS expression in melanoma cells results in reduced proliferation
In line with the acquisition of an invasive transcriptional state, the GSEA on BORIS-induced DEGs revealed a negative enrichment for processes involved in proliferation. To investigate the effect of BORIS expression on proliferation we induced BORIS expression with increasing concentration of dox. Expression of BORIS at each time point was confirmed using immunoblot ( Fig. S3A) . We observed a dose-dependent reduction in proliferation over time compared to untreated cells, which was not observed in the control cells (Fig. 4A) . These findings support the hypothesis that BORIS expression reduces proliferation and promotes a more invasive state in melanoma cells. In addition to an effect of BORIS expression on proliferation, BORIS knockdown in breast cancer and colon cancer cell lines was shown to increased apoptosis (23, 50) . To address whether the reduction in proliferation that we observed is due to increased apoptosis, we investigated the effect of BORIS expression on cell death. Compared to control cells, BORIS expression increased the expression of cleaved PARP, a marker for cell death (Fig. 4B) . In addition, we observed an increase in the number of early apoptotic, apoptotic and necrotic cells following BORIS expression compared to controls ( Fig. 4C and D) , indicating that BORIS expression in melanoma cells leads to a slight, though significant, increase in apoptosis. Taken together, our results show that expression of BORIS in melanoma cells leads to decreased proliferative activity, which is in part due to increased apoptosis.
BORIS expression promotes an invasive phenotype in melanoma cells.
The contribution of BORIS expression to an invasive transcriptional state and a reduction in proliferation prompted us to ask if BORIS expression promotes an invasive phenotype. First, we assessed the effect of BORIS overexpression on migration using a transwell assay in two melanoma cells lines (MM057 and MM074) that harbor a proliferative transcriptional state (4).
Inducible BORIS expression was confirmed by immunoblot ( Fig. S3B) . In both cell lines we observed a significant increase in the percentage of migrating cells compared to the controls ( Fig.   5A and B) . Furthermore, we observed a significant increase in the invasive capacity of both cell lines following BORIS expression in a Matrigel transwell invasion assay ( Fig. 5C and D) . Overall, these results demonstrate that BORIS expression leads to an increase in the migratory and invasive potential of the MM057 and MM074 melanoma cell lines.
Discussion
Phenotype switching is a critical process that allows melanoma cells to acquire an invasive state that fuels disease progression (46) . Important for the cellular plasticity required to transition between a proliferative and invasive phenotype is reprogramming of the transcriptional state. Here, we demonstrate that BORIS can alter the gene expression program of melanoma cells in favor of a more invasive phenotype. Transcriptional profiling revealed that genes upregulated in BORIS-expressing cells are enriched among established invasive gene signatures, while downregulated genes are enriched among the proliferative gene signatures. In line with these findings, we showed that BORIS expression resulted in reduced proliferation, whereas the migratory and invasive abilities of melanoma cells were enhanced. Together, these data indicate that expression of BORIS contributes to the switch from a proliferative towards an invasive state at both the transcriptional and phenotypic level in melanoma cell lines.
In contrast to ubiquitously expressed CTCF, BORIS expression is restricted to the testis (19) and
becomes aberrantly re-activated in various types of cancer, including melanoma (42) . Here we confirm BORIS expression at the mRNA level (36, 44) and demonstrate BORIS protein expression in melanoma cell lines. Noteworthy, we observe BORIS protein expression in 3 cell lines with low to undetectable BORIS mRNA expression, indicating that BORIS mRNA expression is not proportional to BORIS protein level. This discordance between BORIS mRNA and protein has been reported previously (51) and is proposed to be due to a short half-life of the BORIS transcript and high protein stability (52) .
Our finding that altered BORIS expression leads to large-scale changes in gene expression was expected, as BORIS is known to act as a transcriptional regulator (24, 25, 29, 33) . In addition, it reflects the numerous cellular processes that BORIS is involved in (42, 53) , many of which are altered during carcinogenesis. Multiple studies found that increased BORIS expression is linked to poor prognosis and more advanced stages of disease, hence BORIS being considered an oncogene (54) (55) (56) (57) . Nevertheless, one study showed that BORIS overexpression in cancer cell lines results in a similar phenotype as forced expression of the tumor suppressor CTCF (58) . Our data indicates a pro-invasive role for BORIS in melanoma and supports the notion that BORIS acts prooncogenic. While an oncogenic phenotype is associated with fast proliferation, one of the characteristics of phenotypic switching towards an invasive state is inhibition of proliferation (1) .
We indeed demonstrated decreased proliferation upon BORIS overexpression, which is in agreement with previous studies reporting reduced proliferation upon ectopic BORIS expression in both primary cells and various cancer cell lines (58, 59) . Though the literature regarding proliferation in the context of BORIS is not uniform, as others have reported increased proliferation upon BORIS overexpression (24, 27, 50) . Given the large-scale transcriptional changes, additional effects of BORIS expression on melanoma cell biology are very likely.
However, at the moment, other functional roles for BORIS in melanoma have not yet been investigated.
The large number of genes that make up the signatures representing the proliferative and invasive state highlight the complexity that underlies the process of phenotype switching. Multiple transcription factors, signalling pathways and EMT-related genes are important to establish the transitions. Many of these factors are likely involved at different stages of phenotype switching, marked by a transcriptional profile between the proliferative and invasive state (5, 60) , and contribute to partial or intermediate phenotype switching (10, 16, 61) . Our observation that BORIS expression has no effect on MITF, ZEB1 or ZEB2 expression, suggest that the MM057 melanoma cells have already undergone a partial switch. This is consistent with their ability to migrate and invade even in the absence of BORIS expression as well as the lack of CDH1 expression in the control cells, indicating that the equilibrium between ZEB1/2 and E-cadherin might already be in favor of an invasive phenotype in the MM057 cells. Interestingly, we observe increased expression of the EMT transcription factor SNAIL (SNAI1). Ectopic SNAIL expression in human melanoma cells is reported to induce EMT features, which was accompanied by increased expression of TGFbeta, IL-10 and thrombospondin 1 (48) . A bidirectional regulation between TGF-beta and SNAIL exists, as TGF-beta can also upregulate SNAIL expression (48) . In addition, SNAIL expression can be induced by SPARC (49) , a matricellular protein involved in cell-matrix interactions that promotes EMT-like changes (62) and is associated with the metastatic potential of melanoma (63, 64) . We showed that in BORIS-expressing melanoma cells SNAI1, SPARC and TGFB1 expression is increased. Furthermore, expression of a striking number of TGF-beta family members is increased, indicating activation of TGF-beta driven signaling, which is an important mark of the invasive signature (1, 4) . Based on our findings, we propose that BORIS expression induces partial phenotype switching via upregulation of SPARC and TGF-beta signaling that leads to SNAI1 expression. Currently, the mechanisms behind BORIS-mediated transcriptional changes remain elusive, though they likely involve competition with CTCF for DNA binding sites, direct promoter regulation, epigenetic modifications, or chromatin looping.
Our observation that BORIS-expressing melanoma cells have increased migratory and invasive abilities are in agreement with previous studies that demonstrated that BORIS overexpression promoted EMT in liver cancer cell lines (25) as well as the CD44/CD133 positive subpopulation of the IMR-32 neuroblastoma cell line (65) . However, in contrast, Alberti et al., revealed that BORIS knockdown promotes EMT in MCF7 breast cancer cells (66) . These studies suggest a cell type dependent role for BORIS in cancer progression.
Taken together, our study demonstrates that BORIS contributes to melanoma progression by intrinsically rewiring gene expression to promote an invasive phenotype. Furthermore, these results indicate that BORIS is an important transcriptional regulator during phenotype switching in melanoma and provide a rationale for further studies into BORIS' role as an invasion promoting transcriptional regulator. 
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